Daiichi Sankyo launches malignant glioma treatment Delytact in Japan

Tokyo: Daiichi Sankyo Company, Limited has recently announced that the company has launched DELYTACT (teserpaturev/G47∆)*1, an oncolytic virus developed by the company in collaboration with Professor Tomoki Todo (hereinafter, Dr. Todo) of the Institute of Medical Science, The University of Tokyo.

DELYTACT received conditional and time-limited marketing approval in Japan as a regenerative medical product for treatment of malignant glioma in June 2021 based on results from a Japanese phase 2 clinical trial (investigator-initiated trial) in patients with glioblastoma* (a type of malignant glioma*) conducted by Dr. Todo.

For the time being, DELYTACT will be commercially available only at hospitals that served as trial sites. Daiichi Sankyo will establish a stable supply system of the medicine as soon as possible. 

Daiichi Sankyo to offer DELYTACT as a new option for the treatment of malignant glioma and to contribute to the high unmet medical needs of patients suffering from this brain cancer.

Read also: Takeda Pharma Chief asks transparency in virus vaccine rollout